Surrozen (Surrozen) Debt-to-Equity : 0.09 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Surrozen Debt-to-Equity?

Surrozen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.50 Mil. Surrozen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.88 Mil. Surrozen's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $37.94 Mil. Surrozen's debt to equity for the quarter that ended in Dec. 2023 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Surrozen's Debt-to-Equity or its related term are showing as below:

SRZN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.08 Max: 0.2
Current: 0.09

During the past 4 years, the highest Debt-to-Equity Ratio of Surrozen was 0.20. The lowest was 0.07. And the median was 0.08.

SRZN's Debt-to-Equity is ranked better than
61.4% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs SRZN: 0.09

Surrozen Debt-to-Equity Historical Data

The historical data trend for Surrozen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen Debt-to-Equity Chart

Surrozen Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.20

0.07

0.09

Surrozen Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial									0.07	0.08	0.08	0.09	0.09

Competitive Comparison of Surrozen's Debt-to-Equity

For the Biotechnology subindustry, Surrozen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Surrozen's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surrozen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Surrozen's Debt-to-Equity falls into.

Surrozen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Surrozen's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.497	+	0.882)	/	37.935
	=	0.09

Surrozen's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.497	+	0.882)	/	37.935
	=	0.09

Surrozen (NAS:SRZN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Surrozen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Surrozen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Surrozen (Surrozen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.surrozen.com

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS).

Executives

Yang Li	officer: Exec. Vice President, Research	C/O SURROZEN, INC., 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Anna Berkenblit	director	830 WINTER STREET, WALTHAM MA 02451
Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Blutt Mitchell J Md	director, 10 percent owner	1370 AVENUE OF THE AMERICA, SUITE 3301, NEW YORK NY 10019
Christopher Y Chai	director	2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Mary Haak-frendscho	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Wen-chen Yeh	officer: Chief Scientific Officer	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
House Joshua Cory	other: Former VP Business Development	C/O CONSONANCE-HWF ACQUISITION CORP, 1 PALMER SQUARE, SUITE 305, PRINCETON NJ 08540
Geertrui Vanhove	officer: Chief Medical Officer	1333 S. SPECTRUM BLVD #100, CHANDLER AZ 85286
Charles O Williams	officer: Chief Financial Officer	C/O HERITAGE FINANCIAL GROUP, 721 NORTH WESTOVER BOULEVARD, ALBANY GA 31707
Mace Rothenberg	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Donald J Santel	other: Former Director	4362 24TH STREET, SAN FRANCISCO CA 94114
David J Woodhouse	director	630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Iii Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158